pStathmin(S38) in endometrial carcinoma ; survival and targeted therapy
INTRODUCTION
Stathmin is a cytosolic phospho-protein known to be over-expressed in several malignancies (1). It is suggested to be a marker of PTEN loss (2) and to play a role in tumor progression (1, 3) . Further, it is considered important in signal transduction and involved in biological processes such as cell cycle progression, apoptosis and cell migration (1). Microtubular destabilization by Stathmin is suggested to happen through promotion of microtubule catastrophe or by preventing tubulin incorporation in growing microtubules (4) . Stathmin protein function is regulated at a post-translational level by different mechanisms, of which phosphorylation is the most studied (1). Thus, Stathmin has 4 Serine phospho sites (Ser16, -25, -38 and -63), and phosphorylation is shown to inactivate Stathmin's destabilizing effect on microtubules (5-7). Expression of Stathmin and the regulation of protein activity by phosphorylation are important for cell division; inactivation of Stathmin by phosphorylation is critical for proper formation of microtubules and the mitotic spindle, and thereby for entry into mitosis (7) , whereas Stathmin's de-stabilizing effects on microtubules are important to disassemble the mitotic spindle as the cells move through late stages of mitosis (8) . During M-phase progression, Cyclin Dependent Kinases (CDKs) 1/2 phosphorylate Ser25 and Ser38 and precede phosphorylation of Ser16 and Ser63 by other kinases, allowing the mitotic spindle to be properly organized (1, 7). Ser38 is suggested to be phosphorylated also by kinases belonging to the MAPK family as well as the PI3Kinase pathway (1, 9).
Stathmin protein expression has recently been reported to be a prognostic marker in endometrial cancer (10) as well as in breast and urothelial carcinomas (11, 12) , and has also been suggested as a predictive marker for response to taxane treatment in cancer (13) (14) (15) .
Here, we hypothesized that immunohistochemically determined cellular levels of Stathmin phosphorylated at Serine38 [pStathmin(S38)] relates to tumor phenotype and survival in endometrial carcinoma. We also wanted to explore possible associations between high pStathmin(S38) in endometrial carcinoma ; survival and targeted therapy pStathmin(S38) and potential targets for therapy in pStathmin(S38)-high cases. By analyzing two independent patient series, we identify and validate for the first time, that pStathmin(S38) adds independent prognostic information for cancer patients, as shown here for endometrial carcinomas. A link between strong pStathmin(S38) tissue staining and high tumor cell proliferation as well as the PI3Kinase pathway is supported by several measures, and transcriptional signatures associated with high pStathmin(S38) suggest drugs targeting PI3Kinase/mTOR signaling and HSP90 as particularly relevant to test in clinical trials of endometrial carcinomas.
MATERIAL AND METHODS

Patients and tumor samples
Formalin fixed and paraffin embedded (FFPE) as well as fresh frozen endometrial carcinoma tumor specimens were retrieved from the Bergen Gynecologic Cancer Biobank, Norway, and related to clinical and histopathologic data in two independent series: I) The primary investigation set of fresh frozen and FFPE tumor tissue in parallel (n=122/518, respectively), prospectively collected from May 2001 to December 2010; II) The retrospectively collected population based validation series consisting of FFPE tumor tissue from 286 patients diagnosed from 1980-1990 (16) . All patients were treated at the Section for Gynecological Cancer, Haukeland University Hospital, a referral hospital for patients in the Western Health Region of Norway including Hordaland County, Bergen, Norway, as previously reported (17) .
Before extracting DNA and RNA from tumors in the primary investigation series, hematoxylin stained frozen sections were evaluated to ensure high tumor purity in the available tissue (more than 80% tumor purity for the majority of cases). DNA and RNA were 
Tissue microarray (TMA)
Hematoxylin and eosin (H&E) stained slides from tumors were evaluated to identify areas with high tumor purity for retrieval of three 0.6 mm tissue cylinders to be mounted in a
Research. pStathmin(S38) in endometrial carcinoma ; survival and targeted therapy recipient paraffin block, using a custom-made precision instrument (Beecher Instruments, Silver Spring, MD, USA), as previously described (21, 22) . TMA sections of 5µm were subsequently dewaxed with xylene/ethanol for immunohistochemical staining.
Immunohistochemistry
Details on the Stathmin staining are previously reported (10) . For pStathmin(S38), staining procedures were performed using the Leica Microsystems Bond III Autostainer automated slide processing equipment. Heat Induced Epitope Retrieval was applied for ten minutes in pStathmin(S38) in endometrial carcinoma ; survival and targeted therapy Assessment of Ki67, mitotic count, and S-phase fraction in the validation series has previously been described (18, 24) . Briefly, Ki67 IHC staining was assessed in 5µm full sections. After microwave epitope retrieval, the sections were incubated with a Ki67 polyclonal antibody (code no. A-047, Dako Cytomatation Nordic Oslo, Norway). The percentage of staining positively stained nuclei was calculated from the area with most intense staining ("hot spot"), by counting ~1000 tumor cells at x1000 magnification.
The number of mitoses (e.g. 'mitotic count') was counted in 'hot spot' areas of highest histologic histologic grade and highest mitotic activity, and counted in 10 high-power fields (x400).
Adjusted S-phase fraction, defined as the area between G1 and G2/M peaks, was calculated from DNA flow cytometric analyses from fresh, ethanol fixed tissue and estimated according to the method by Baisch et al, (25) .
Evaluation of staining
Blinded for patient characteristics and outcome, the slides were evaluated by two of the authors (E.W. and H.S.), using a standard light microscope. A semi-quantitative grading system incorporating staining intensity (score 0-3) and area of tumor with positive staining (0= no staining, 1= <10%, 2= 10-50% and 3= >50% of tumor cells) was applied. Staining index (SI) was calculated as the product of staining intensity and area ranging from 0-9, as described in several publications (26, 27) . If heterogeneity was seen for the three cylinders of each case, the three cylinders were given one overall averaged score similar to the approach pStathmin(S38) in endometrial carcinoma ; survival and targeted therapy described (32, 33) . Previously published PTEN sequencing data from the retrospective validation series (34) were included to assess whether PTEN mutations were associated with pStathmin(S38) levels.
Oligonucleotide DNA microarray analyses
Extracted RNA was hybridized to Agilent Whole Human Genome Microarrays 44k (Cat.no. G4112F) according to the manufacturer's instructions (www.agilent.com). Arrays were scanned using the Agilent Microarray Scanner Bundle. Microarray signal intensities were determined using J-Express (www.molmine.no). Median spot signal data were used as intensity measure. The expression data were quantile normalized. False discovery rate (FDR) <0.1 was used as cut-off when identifying genes and pathways significantly differentially expressed between tumors with high versus low pStathmin(S38); using, respectively, Significance Analysis of Microarrays (SAM) (35) 
Connectivity Map
Research. pStathmin(S38) in endometrial carcinoma ; survival and targeted therapy 13 The correlation between the global expression pattern and potential new therapeutics for patients with high tumor pStathmin(S38) was assessed in the primary investigation cohort.
Associations between the pStathmin(S38) transcription signature and drug signatures in the Connectivity Map database (38) were explored. Genes differentially expressed (FDR <0.1) between tumor subsets of low and high pStathmin(S38) levels were included in the signature as the basis for the analyses in Connectivity Map.
Statistical analyses
Data were analyzed using SPSS (Statistical Package of Social Sciences), version 20.0 (SPSS, Inc., Chicago, IL). Probability of < 0.05 was considered statistically significant, except for the DNA microarray analyses. Mann-Whitney U test and the Spearman's rank correlation was used for analyses of continuous variables between categories. Univariate survival analyses of time to death due to endometrial carcinoma (disease specific survival) and time to recurrence for patients without metastases at time of diagnosis (recurrence free survival) were performed using the Kaplan-Meier method. Entry date was the date of primary surgery. Patients who died from other causes were censored at the date of death. Differences in survival between groups were estimated by two sided log-rank (Mantel Cox) tests. Categories were compared using Pearson's chi-square or Fisher's exact test when appropriate. Cox' proportional hazards method was used for multivariate survival analyses. The variables were visually examined by a log-minus-log plot to check the assumptions about proportionality before incorporation into (Table 1) . Also, high pStathmin(S38) predicted lymph node metastasis (OR=3.3, P<0.001). In the primary investigation series, a trend towards high pStathmin(S38) in serous and undifferentiated carcinomas and carcinosarcomas compared to clear cell carcinomas (P=0.1) was seen. However, this finding was not present in the smaller validation series. High pStathmin(S38) was also associated with shorter disease specific survival in both patient series studied (Figure 1C-D 
survival impact if cured, but with a likely quality of life impact.
In multivariate survival analyses, high pStathmin(S38) independently predicted poor prognosis adjusted for histologic subtype, histologic grade and myometrial infiltration among patients with tumors confined to the uterus (FIGO stage I/II) ( Table 2 ). This pattern of prognostic impact of high pStathmin(S38) expression was also seen in the validation series (HR 2.2, 95% CI: 0.96-4.9, p=0.07) when adjusted for the same histopathologic variables. pStathmin(S38) IHC staining and scoring in TMAs were compared to whole section staining in 52 randomly selected cases (primary investigation series). Kappa value for reproducibility was 0.77, regarded as good strength of agreement, supporting that assessment in TMA sections are valid, also in line with previous studies for other tissue markers. (18) pStathmin(S38) expression adds prognostic information to Stathmin. pStathmin(S38) was significantly correlated to Stathmin expression (Table 1) . As both pStathmin(S38) and Stathmin were shown to be independent prognostic markers in separate models, we further examined how pStathmin(S38) performed as a prognosticator compared to Stathmin. In a multivariate survival analysis of the primaryinvestigation series, including both Stathmin and pStathmin(S38) expression and adjusting for histologic subtype, histologic grade and myometrial infiltration, pStathmin(S38) maintained independent prognostic impact (HR 1.8, 95% CI 1.0-3.1, p=0.05), while Stathmin did not (Supplementary Table 1 pStathmin(S38) in endometrial carcinoma ; survival and targeted therapy pStathmin(S38) was still significant in the validation series (HR 1.8, P=0.04) in contrast to Stathmin (P=n.s), whereas neither pStathmin(S38) nor Stathmin were significant in the primary investigation series, possibly reflecting more extensive and systematic lymph node sampling and staging in this cohort. pStathmin(S38) loses its independent association with survival when adjusting for adjuvant therapy (P=0.15, both patient cohorts).
Integrated analyses associate high pStathmin(S38) expression to tumor cell proliferation.
Unsupervised clustering of gene expression data defined three clusters of which two were enriched for cases with an aggressive phenotype. High pStathmin(S38) was more frequent (P=0.03) in these two clusters also showing worse survival compared to the third cluster (Supplementary figure 2) . Still, many of the cases segregating into the worse outcome clusters did not show high pStathmin(S38) level, indicating that transcriptional alterations segregating endometrial cancer into phenotypic subtypes represent more complex alterations and no complete overlap with pStathmin(S38) level.
Transcriptional differences between tumors with high versus low levels of pStathmin(S38)
were furthermore explored by pathway analyses (GSEA) of DNA microarray data (primary investigation series). Gene sets comprising genes involved in cell cycle progression and cell proliferation were highly enriched in tumors with high pStathmin(S38) by IHC (Supplementary Table 3 Also, high Stathmin protein expression was correlated with similar strength to high mitotic count and proportion of Ki67 positive tumor cells, but not to S-phase fraction ( Figure 2D-F) .
In sum, our data support that pStathmin(S38) is related to tumor cell proliferation and adds important and clinically relevant prognostic information in endometrial cancer patients, also among presumed low risk cases.
PI3K/mTOR are suggested as potential targets in tumors with high pStathmin(S38)
Connectivity Map version 02 (38) were the top ranked therapeutics identified as potential drugs to patients with high tumor pStathmin(S38), as listed in Table 3 .
We then explored the correlation between PI3Kinase pathway alterations and pStathmin(S38) expression in the tumors. High pStathmin(S38) associated significantly with amplification of the 3q26 region harboring PIK3CA as estimated by SNP array, increased absolute copy number of PIK3CA, estimated by FISH, and a high PI3K activation score (37), although not with PTEN immunostaining, PTEN mutations or PIK3CA mutations (Table 4) 
DISCUSSION
Stathmin is shown to be a prognostic marker in various cancer types, such as breast and endometrial cancer (2, 32) , and is recently reported to predict lymph node metastases in a large multicenter study of endometrial cancer (10) . In contrast, the prognostic impact and possible clinical utility of phosphorylated Stathmin has not been much studied in human cancers (1, 3, 39), although the impact of phosphorylation at different Stathmin phospho sites has been explored in some experimental models, mainly in relation to the effects on microtubule formation, proliferation, cell migration and cancer invasion (3, 39, 40) . In this study of endometrial cancer, pStathmin(S38) was strongly associated with different markers of tumor proliferation and showed a significant and independent association with patient survival above the information given by standard clinico-pathologic features and by Stathmin expression. A prognostic impact of pStathmin(S38) has, to our knowledge, not been previously shown for any cancer type. Our findings have been validated in an independent patient cohort and indicate that pStathmin(S38) might be of practical use in the management of endometrial carcinoma patients, also in regard to identifying patients with higher risk for recurrent disease amongst presumed low risk cases. 
pStathmin(S38) in endometrial carcinoma ; survival and targeted therapy prognostic impact when analyzed in a Cox model including from FIGO stage where 78% of the patients had been subjected to staging lymphadenectomy. Still, pStathmin(S38) level showed independent prognostic impact in all other Cox models explored. Importantly, our study was not designed to assess the value of lymphadenectomy, but future studies should explore if pStathmin(S38) may be useful in a context of "molecular staging" instead of staging lymphadenectomy also associated with side effects.
Both pStathmin(S38) and Stathmin IHC expression were strongly associated with the different proliferation markers investigated, possibly reflecting that both phosphorylated and Here, we found a similar pattern for pStathmin(S38), and in addition an association between high pStathmin(S38) and increased absolute PIK3CA copy number by FISH. Various molecular alterations may potentially contribute to PI3K signaling activation (42) , including PIK3CA amplifications. In line with this, we find higher PIK3CA copy number in pStatmhin(S38) high cases, potentially contributing to PI3K signaling activation in these tumors. Mutations in PIK3CA exons 1-20 and PIK3R1 are described for endometrial carcinomas (43) (44) (45) . Several of the mutations in exon 9 and exon 20 are previously associated with aggressive histopathologic features and suggested to be PI3K signaling activating mutations (44) . Other PIK3CA and PIK3R1 mutations, not included in the present study, are also suggested to activate the PI3K signaling pathway and further testing for any potential link to pStathmin(S38) level is needed. This is also the case for other PI3K related molecular alterations not assessed in this study. 
CONCLUSION:
Our study supports that pStathmin(S38) is an independent prognostic marker in endometrial carcinomas and significantly associated with tumor cell proliferation. To our knowledge, pStathmin(S38) is a prognostic biomarker not previously reported for human cancers. The present data also suggest a potential for drugs inhibiting the PI3K signaling pathway to pStathmin(S38)-high cases in particular, and we provide a rationale for further studies testing pStathmin(S38) as predictive marker for response to PI3K/mTOR/HSP90 inhibitors. The expression changes from the compounds tested were scored according to the pStathmin(S38) level signature. The p-value for each compound represents the distribution of this score in the N instances, compared with the distribution of these scores amongst all compounds tested, using a permutation test (Lamb, Science 2006 e Data from the retrospective validation series. f The antibody 6H2.1 was tested; there was no significant association between pStathmin(S38) and a second antibody tested (A2B1, P=0.3).
FIGURE LEGENDS:
g Any PTEN mutations versus wild-type samples.
